Table 1.
Demographic and clinical characteristics of participants
| TDF (n=12) | Placebo (n=5) | |
|---|---|---|
| Age, years | 28·3 (22·2–33·5) | 33·6 (28·8–38·1) |
| Race | ||
| White | 8 (67) | 2 (40) |
| Black | 3 (25) | 0 |
| Asian | 0 | 1 (20) |
| >1 race | 1 (8) | 0 |
| Not reported | 0 | 2 (40) |
| Ethnicity | ||
| Hispanic | 2 (17) | 1 (20) |
| Non-Hispanic | 10 (83) | 4 (80) |
| Relationship status | ||
| Married | 1 (8) | 2 (40) |
| Single | 2 (17) | 1 (20) |
| Cohabitating | 5 (42) | 1 (20) |
| In relationship, not living together | 4 (33) | 1 (20) |
| Contraception | ||
| Oral contraceptive pills | 7 (58) | 3 (60) |
| DMPA | 1 (8) | 1 (20) |
| Intrauterine device | 2 Copper, 1 LNG (25) | 1 LNG (20) |
| Implant | 1 (8) | 0 |
| Self-report of condom use | ||
| Never | 8 (67) | 4 (80) |
| Sometimes | 4 (33) | 1 (20) |
| Sex acts month prior to screening | 6·5 (4·2–10) | 12(10·5–17·5) |
| Partner circumcised | 7 (58) | 4 (80) |
| History of receptive anal intercourse | 6 (50) | 4 (80) |
| History of STI | 4 (33) | 1 (20) |
| HSV- 2 seropositive | 2 (17) | 1 (20) |
| Prior NuvaRing use | 2 (17) | 0 |
| Ever pregnant | 3 (25) | 2 (40) |
| Vaginal pH at enrollment | 4·6 (3·8–5·1) | 4·9 (3·9–5·5) |
| Nugent score at enrollment | 2·5 (1–3·2) | 7(0·5–8) |
n, number; TDF, tenofovir disoproxil fumarate; DMPA; depot medroxyprogesterone acetate; LNG, levonorgestrel; STI, sexually transmitted infection; HSV-2 herpes simplex virus type 2
Categorical variables reported as number (%); continuous variables reported as median (interquartile range [IQR])